공시 • May 11
ZeroStack Corp., Annual General Meeting, Jul 13, 2026 ZeroStack Corp., Annual General Meeting, Jul 13, 2026. Location: dorsey & whitney llp, 66 wellington street west, suite 3400, on m5k 1e6., toronto, Canada 공시 • Jan 08
Flora Growth Corp. Announces Board and Committee Changes Flora Growth Corp. unanimously approved by written consent the appointment of (i) Mr. Larry Zeifman as a director of the Company, as a member of the audit committee of the Board (the "Audit Committee"), as a member of the compensation committee of the Board (the "Compensation Committee"), as a member of the nominating and corporate governance committee of the Board (the "Nominating Committee") and as Chair of the Audit Committee and (ii) Mr. Manfred Leventhal as Chair of the Nominating Committee. The Board has determined that Mr. Zeifman is an independent director, meets the applicable standards for Audit Committee service under both the Nasdaq Stock Market Rules and Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and meets the applicable standards for Compensation Committee service under the Nasdaq Stock Market Rules. Mr. Zeifman's appointment fills the vacancy on the Board, the Compensation Committee and the Nominating Committee which resulted from the passing of Harold Wolkin on August 25, 2025. 공시 • Sep 23
Flora Growth Corp. has filed a Follow-on Equity Offering in the amount of $2.12 million. Flora Growth Corp. has filed a Follow-on Equity Offering in the amount of $2.12 million.
Security Name: Common Shares
Security Type: Common Stock
Transaction Features: At the Market Offering 공시 • May 03
Flora Growth Corp. announced that it expects to receive $1.157928 million in funding Flora Growth Corp. announced that it has entered into a securities purchase agreement with certain investors in connection with the issuance and sale by the Company to the Investors via a private placement of an aggregate of 3,133,011 common shares of the Company, no par value per share at a purchase price of $0.30 per share and 726,992 pre-funded warrants of the Company at a purchase price of$0.2999 per warrant each to purchase one Common Share which shall be immediately exercisable and expire when exercised in full, at an exercise price of $0.0001 per share for the aggregate gross proceeds of up to $ on May 2, 2025. The Company will reimburse the Investors a non-accountable amount of $15,000 for all costs and expenses of outside counsel and disbursements of Bevilacqua PLLC, counsel to one of the Investors, which shall be withheld by such Investor from its purchase price at the closing date of the Private Placement. The net proceeds from the sale of the Common Shares and Pre-funded Warrants were approximately $1,100,000 after deducting estimated expenses relating to the Private Placement. The Securities Purchase Agreement includes customary representations, warranties and covenants by the Company and the Investors. Additionally, the Company has agreed to provide the Investors with customary indemnification under the Securities Purchase Agreement against certain liabilities, including liabilities under the Securities Act of 1933, as amended. 공시 • Apr 17
Flora Growth Corp., Annual General Meeting, Jul 21, 2025 Flora Growth Corp., Annual General Meeting, Jul 21, 2025. Location: dorsey & whitney llp, 66 wellington street west, suite 3400, on m5k 1e6., toronto Canada 공시 • Mar 01
Flora Growth Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market On February 25, 2025, Flora Growth Corp. received a notice from the Listing Qualifications Department of the Nasdaq Stock Market stating that for 30 consecutive business days the Company's common shares did not maintain a minimum closing bid price of $1.00 per share as required for continued listing under Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Common Shares. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until August 25, 2025, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Common Shares must be at least $1.00 per share for a minimum of ten consecutive business days before August 25, 2025, at which time the Staff will provide written notification to the Company that it complies with the Minimum Bid Requirement, unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Common Shares does not achieve compliance by August 25, 2025, the Company may be eligible for an additional 180-day period to regain compliance, provided that it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards of the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, for example, by effecting a reverse stock split, if necessary. The Company intends to actively monitor the closing bid price of the Common Shares and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement under the Nasdaq Listing Rules. 공시 • Feb 12
Flora Growth Corp. Appoints Patrick Moloney as Head of Product Development for Its Accessory Brand, Vessel Flora Growth Corp. announced the appointment of Patrick Moloney as Head of Product Development for its accessory brand, Vessel. Mr. Moloney brings over two decades of product innovation and leadership experience, having held senior roles in product development at several globally recognized companies. His expertise in design and strategy will help drive Vessel's continued growth in the premium accessories market. Mr. Moloney's career highlights include serving as Design Manager on New Product Innovation at Dyson, where he was responsible for leading a team in developing consumer products. His experience in the highly competitive consumer goods sector was further honed during his tenure as Senior Manager of New Sciences at British American Tobacco, where he was tasked with creating next-generation product offerings. Most recently, as Chief Product Officer at InLab Ventures, Mr. Moloney led the development of innovative products and services across multiple industries, focusing on sustainability and user experience.Mr. Moloney is an inventor of over 300 patents who has brought to market iconic inventions, including the Dyson Supersonic Hairdryer and Dyson Airblade Tap, as well as developing foundational concepts for Dyson's floorcare range. At British American Tobacco, Mr. Moloney's contributions resulted in over 170 inventions and 120 patent filings, representing about 25% of British American Tobacco's total filings during his tenure.in his new role, Mr. Moloney will oversee Vessel's product development, leveraging his extensive experience to drive innovation, enhance product quality, and strengthen Vessel's market position. As the cannabis accessories market evolves, his appointment underscores Flora's commitment to providing consumers with the highest-quality products and elevating the Vessel brand. 공시 • Feb 06
Flora Growth Corp. (NasdaqCM:FLGC) acquired United Beverage Distribution Inc from a group of shareholders for $3.7 million. Flora Growth Corp. (NasdaqCM:FLGC) entered into a share purchase agreement to acquire United Beverage Distribution Inc from a group of shareholders for $3.7 million on January 30, 2025. The consideration consists of 923,744 common stock of Flora and promissory notes in an aggregate principal amount of $2.8 million to be issued to the sellers. The agreement were unanimously approved by the disinterested directors of Flora.
Flora Growth Corp. (NasdaqCM:FLGC) completed the acquisition of United Beverage Distribution Inc from a group of shareholders on February 4, 2025. 공시 • Dec 17
Flora Growth Corp. has completed a Follow-on Equity Offering in the amount of $3.5625 million. Flora Growth Corp. has completed a Follow-on Equity Offering in the amount of $3.5625 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 2,850,000
Price\Range: $1.25
Discount Per Security: $0.0875
Transaction Features: Registered Direct Offering 공시 • Dec 15
Flora Growth Corp. has filed a Follow-on Equity Offering in the amount of $3.5625 million. Flora Growth Corp. has filed a Follow-on Equity Offering in the amount of $3.5625 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 2,850,000
Price\Range: $1.25
Transaction Features: Registered Direct Offering 공시 • Dec 13
Flora Growth Corp. has withdrawn its Follow-on Equity Offering in the amount of $3.794 million. Flora Growth Corp. has withdrawn its Follow-on Equity Offering in the amount of $3.794 million.
Security Name: Common Shares
Security Type: Common Stock
Transaction Features: At the Market Offering New Risk • Nov 17
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$18m Forecast net loss in 1 year: US$1.6m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.9m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$1.6m net loss next year). Market cap is less than US$100m (€14.8m market cap, or US$15.6m). Reported Earnings • Nov 16
Third quarter 2024 earnings released: US$0.28 loss per share (vs US$0.11 profit in 3Q 2023) Third quarter 2024 results: US$0.28 loss per share (down from US$0.11 profit in 3Q 2023). Revenue: US$12.5m (down 28% from 3Q 2023). Net loss: US$3.77m (down US$4.52m from profit in 3Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe. 공시 • Oct 11
Flora Growth Corp. Appoints Manfred Ziegler as Managing Director Flora Growth Corp. announced the appointment of Dr. Manfred Ziegler as a Managing Director. Dr. Ziegler, a renowned figure in the pharmaceutical industry, brings decades o expertise, notably his leadership as Managing Director of CC Pharma and his pivotal role in the sale of CC Pharma to Tilray, one of the world's leading cannabis companies. With the appointment of Dr. Ziegler, Flora Growth is poised to accelerate its ambition to become one of the leading cannabis companies in Germany. His strategic leadership and proven ability to drive growth in complex markets will be instrumental as Flora expands its operations in Germany, targeting increased market share and a stronger foothold in Europe's rapidly evolving cannabis sector. Dr. Ziegler's tenure at CC Pharma marked a period of growth and strategic innovation. As Managing Director, he transformed the company into one of Europe's leading pharmaceutical distributors, with a robust portfolio and a significance presence in the European market. His leadership was instrument in the successful acquisition of CC Pharma by Tilray. The sale of CC Pharma to Tilray was a significant transaction in the cannabis and pharmaceutical sectors. This acquisition positioned Tilray as a key player in the European medical cannabis market, leveraging CC Pharma's established distribution network to expand its reach in the rapidly growing sector. Dr. Manfred Ziegler is a seasoned executive with over 30 years of experience in the pharmaceutical and healthcare sectors, recognized for his expertise in corporate restructuring and business transformation. Prior to his tenure at CC Pharma, Dr. Ziegler held leadership roles at several prominent companies, where he managed complex international operations and contributed to substantial revenue growth. His track record of strategic realignment and operational efficiency has made him a respected leader in the industry. In his role as Managing Director, Dr. Ziegler will work closely with Flora's executive team, providing insights and guidance on international distribution strategies, regulatory compliance, and market expansion. His understanding of the German market, combined with his experience in overseeing large- scale transactions, will be critical as Flora accelerates its growth plans and pursues opportunities in Europe. One of Dr. Ziegler's key objectives will be to spearhead the launch of the Company's parallel import business in Germany. Parallel importing involves purchasing pharmaceutical products from other EU countries where prices are lower, and then importing them into Germany to sell at competitive rates. This practice is highly regulated but provides an opportunity to reduce costs for consumers and increase Flora's market presence. Dr. Ziegler's vast experience in the pharmaceutical sector, particularly in navigating regulatory complexities and optimizing supply chains, will be critical in establishing Flora as a leader in this space, helping the company provide affordable, high-quality products to the German market. 공시 • Sep 12
Flora Growth Corp. Announces Board Changes Flora Growth Corp. announced the appointment of Harold Wolkin as an independent director on its Board of Directors. In this role, Mr. Wolkin will also serve as a member of each of the Company's committees, including as Chair of the Audit Committee. Mr. Wolkin brings over 30 years of progressive experience in the finance sector, having held significant roles in investment banking, including positions at BMO Capital Markets and Dundee Capital Markets. His extensive background and expertise will be instrumental in guiding Flora's financial strategy and governance as the Company continues to expand its global operations. In addition to his new role at Flora, Mr. Wolkin currently serves on the boards of several publicly listed companies. He is the Audit Committee Chair at Baylin Technologies Inc, the Lead Independent Director and Audit Committee Chair at Cipher Pharmaceuticals, Chairman of Femto Technologies Inc. Mr. Wolkin has also made notable contributions to the financial community as a past President of the CFA Society Toronto, and he has been a member of the Chartered Financial Institute since 1980, holding the Chartered Financial Analyst (CFA) designation. Mr. Wolkin holds a Bachelor of Arts in Economics from York University and a Master of Arts in Economics and Finance from the University of Toronto. He is also a graduate and member of the Institute of Corporate Directors, further underscoring his commitment to excellence in corporate governance. Concurrently with Mr. Wolkin's appointment, Flora announced the appointment of Mr. Clifford Starke as Chairman of the Board of Directors. Mr. Starke is currently the Chief Executive Officer of the Company. 공시 • Sep 01
Flora Growth Announces Update on Compliance with the Audit Committee Composition Requirements of Nasdaq Listing Rule 5605(c)(2)(A) After giving effect to Mr. Kevin Taylor's resignation, the audit committee of the Board of Directors (the ‘Board’) of Flora Growth Corp. (the ‘Company’), no longer had three independent members as required by Nasdaq Listing Rule 5605(c)(2)(A). The Company informed Nasdaq of the foregoing on August 27, 2024. On August 29, 2024, the Company appointed Mr. Harold Wolkin as an independent director and member of each of the Company's audit committee, compensation committee and nominating and corporate governance committee, thereby regaining compliance with Nasdaq Listing Rule 5605(c)(2)(A). After giving effect to Mr. Wolkin's appointment, the audit committee of the Board has three independent members as required by Nasdaq Listing Rule 5605(c)(2)(A). The Company informed Nasdaq of the foregoing on August 30, 2024. As a result of the foregoing, the Company expects Nasdaq to confirm that it has regained compliance with the audit committee composition requirements of Nasdaq Listing Rule 5605(c)(2)(A). Reported Earnings • Aug 13
Second quarter 2024 earnings released: US$0.21 loss per share (vs US$5.46 loss in 2Q 2023) Second quarter 2024 results: US$0.21 loss per share (improved from US$5.46 loss in 2Q 2023). Revenue: US$15.7m (down 27% from 2Q 2023). Net loss: US$2.63m (loss narrowed 93% from 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.2% growth forecast for the Personal Products industry in Europe. Board Change • Jul 22
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Strategic Advisor Juan Galan is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 공시 • Jun 06
Flora Growth Corp. (NasdaqCM:FLGC) acquired Australian Vaporizers Pty Ltd. from Lifeist Wellness Inc. (TSXV:LFST) for CAD 0.87 million. Flora Growth Corp. (NasdaqCM:FLGC) entered into a Share Purchase Agreement to acquire Australian Vaporizers Pty Ltd. from Lifeist Wellness Inc. (TSXV:LFST) for CAD 0.87 million on June 4, 2024. The consideration consist of issue of 0.55 million common equity of Flora Growth Corp. having a value of CAD 0.87 million to be issued for common equity of Australian Vaporizers Pty Ltd. As part of the agreement, Flora Growth agreed to acquire 100% of issued and outstanding common shares of Australian Vaporizers. Kronos Capital Partners acted as financial advisor for Lifeist Wellness Inc.
Flora Growth Corp. (NasdaqCM:FLGC) completed the acquisition of Australian Vaporizers Pty Ltd. from Lifeist Wellness Inc. (TSXV:LFST) on June 4, 2024. 
